Last reviewed · How we verify
Vevye®
Vevye is a monoclonal antibody that targets and inhibits the PD-1 receptor.
Vevye is a monoclonal antibody that targets and inhibits the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Melanoma.
At a glance
| Generic name | Vevye® |
|---|---|
| Also known as | Cyclosporine Ophthalmic Solution |
| Sponsor | Baylor College of Medicine |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
By binding to PD-1, Vevye prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively. This results in the activation of T cells and the enhancement of anti-tumor immune responses.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
- Melanoma
- Renal cell carcinoma
- Urothelial carcinoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
- Diarrhea
- Fatigue
Key clinical trials
- Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction (PHASE4)
- Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks (PHASE4)
- A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vevye® CI brief — competitive landscape report
- Vevye® updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI